Press

  • aside

    Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The…

    by
  • aside

    New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which…

    by
  • aside

    Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)…

    by
  • aside

    Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,…

    by
  • aside

    Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,…

    by
  • aside

    ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION

    Isofol Medical AB (publ) today announces that a new patent application was filed, on February 14, 2017, to the US…

    by